(Liver Cancer) Efficacy of Nivolumab in Cancer Patients with Impaired Liver Function
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Anti-PD-1 Antibody Nivolumab in Liver Cancer
- February 27, 2019
- Reading time: 1 minute
Efficacy of the anti-PD-1 antibody nivolumab in patients with advanced hepatocellular carcinoma and impaired liver function
At the ASCO GI 2019 Gastrointestinal Cancers Symposium held in San Francisco, January 17–19, 2019, Dr. Masatoshi Kudo of the Gastroenterology Division, Kinki University Hospital, presented CheckMate 040 Phase 2 clinical trial results for the anti-PD-1 antibody nivolumab in 49 patients with hepatocellular carcinoma and impaired liver function.
The trial administered nivolumab 240 mg every two weeks to patients with hepatocellular carcinoma, continuing until disease progression or intolerable adverse reactions. Primary endpoints included ORR (objective response rate) and DOR (duration of response).
Key results:
- ORR (objective response rate): 10.2%
- DCR (disease control rate): 55.1%
- TTR (time to response): Mean 2.7 months
- DOR (duration of response): Mean 9.9 months
Overall survival (OS):
- Sorafenib-naive patients: OS 9.8 months
- Sorafenib-pretreated patients: OS 7.3 months
Safety: Adverse event rate was 51% (25/49 patients), but the treatment discontinuation rate due to adverse events was only 4.1% (2/49 patients).
Based on these results, continuous nivolumab treatment demonstrated efficacy in patients with advanced hepatocellular carcinoma and impaired liver function, with a low rate of treatment discontinuation due to side effects.
Source: Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. (ASCO GI 2019, Abstract No. 327)
Tags: #LiverCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4